KR20250117836A - 자궁내막증의 치료를 위한 고나도트로핀 방출 호르몬 길항제 투약 요법 - Google Patents

자궁내막증의 치료를 위한 고나도트로핀 방출 호르몬 길항제 투약 요법

Info

Publication number
KR20250117836A
KR20250117836A KR1020257024754A KR20257024754A KR20250117836A KR 20250117836 A KR20250117836 A KR 20250117836A KR 1020257024754 A KR1020257024754 A KR 1020257024754A KR 20257024754 A KR20257024754 A KR 20257024754A KR 20250117836 A KR20250117836 A KR 20250117836A
Authority
KR
South Korea
Prior art keywords
day
patient
administered
dose
amh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257024754A
Other languages
English (en)
Korean (ko)
Inventor
어니스트 루메이
장-피에르 고테랜드
Original Assignee
깃세이 야쿠힌 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 깃세이 야쿠힌 고교 가부시키가이샤 filed Critical 깃세이 야쿠힌 고교 가부시키가이샤
Publication of KR20250117836A publication Critical patent/KR20250117836A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
KR1020257024754A 2017-06-05 2018-06-05 자궁내막증의 치료를 위한 고나도트로핀 방출 호르몬 길항제 투약 요법 Pending KR20250117836A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762515268P 2017-06-05 2017-06-05
US62/515,268 2017-06-05
PCT/EP2018/064768 WO2018224498A1 (en) 2017-06-05 2018-06-05 Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
KR1020197038977A KR102839190B1 (ko) 2017-06-05 2018-06-05 자궁내막증의 치료를 위한 고나도트로핀 방출호르몬 길항제 투약요법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197038977A Division KR102839190B1 (ko) 2017-06-05 2018-06-05 자궁내막증의 치료를 위한 고나도트로핀 방출호르몬 길항제 투약요법

Publications (1)

Publication Number Publication Date
KR20250117836A true KR20250117836A (ko) 2025-08-05

Family

ID=62620835

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257024754A Pending KR20250117836A (ko) 2017-06-05 2018-06-05 자궁내막증의 치료를 위한 고나도트로핀 방출 호르몬 길항제 투약 요법
KR1020197038977A Active KR102839190B1 (ko) 2017-06-05 2018-06-05 자궁내막증의 치료를 위한 고나도트로핀 방출호르몬 길항제 투약요법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197038977A Active KR102839190B1 (ko) 2017-06-05 2018-06-05 자궁내막증의 치료를 위한 고나도트로핀 방출호르몬 길항제 투약요법

Country Status (12)

Country Link
US (2) US11980621B2 (enExample)
EP (1) EP3634418A1 (enExample)
JP (2) JP7348171B2 (enExample)
KR (2) KR20250117836A (enExample)
CN (1) CN110996956A (enExample)
AU (2) AU2018280742B2 (enExample)
CA (1) CA3066190A1 (enExample)
EA (1) EA201992612A1 (enExample)
MA (1) MA49256A (enExample)
MX (1) MX2019014483A (enExample)
SG (1) SG11201911598WA (enExample)
WO (1) WO2018224498A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2912929T5 (en) 2016-09-30 2025-05-09 Sumitomo Pharma Switzerland Gmbh Methods of treating uterine fibroids and endometriosis
US11980621B2 (en) 2017-06-05 2024-05-14 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
EP4509173A3 (en) 2017-06-05 2025-06-04 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
MA54058A (fr) 2018-10-29 2021-09-08 ObsEva SA Compositions et méthodes de traitement de l'endométriose interne et de l'endométriose rectovaginale
EP4009977A2 (en) * 2019-08-08 2022-06-15 ObsEva S.A. Compositions and methods for the treatment of estrogen-dependent disorders
CN113384581B (zh) * 2020-03-12 2023-11-14 成都倍特药业股份有限公司 一种包含促性腺激素释放激素拮抗剂的药物组合物
CA3185151A1 (en) 2020-05-29 2021-12-02 Myovant Sciences Gmbh Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists
EP4243829A1 (en) * 2020-11-11 2023-09-20 Myovant Sciences GmbH Methods of administering relugolix
WO2022179469A1 (zh) * 2021-02-23 2022-09-01 南京明德新药研发有限公司 噻吩并嘧啶二酮类化合物及其应用
CN115232144B (zh) * 2021-04-22 2024-04-02 长春金赛药业有限责任公司 含氮稠环类衍生物、药物组合物及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342760A (en) 1992-06-10 1994-08-30 Abbott Laboratories Determination of estradiol by competitive immunoassay
US5663054A (en) 1995-03-03 1997-09-02 Abbott Laboratories Determination of steroids by competitive immunoassay
US7109171B2 (en) 2000-02-28 2006-09-19 Praecis Pharmaceuticals Inc. Methods for treating FSH related conditions with GnRH antagonists
AU7102201A (en) 2000-07-05 2002-01-14 Yamanouchi Pharma Co Ltd Propane-1,3-dione derivatives
PT1591446E (pt) 2003-01-29 2013-06-12 Takeda Pharmaceutical Compostos de tienopirimidina e sua utilização
CA2531508C (en) 2003-07-07 2013-10-08 Neurocrine Biosciences, Inc. Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
RU2404973C2 (ru) 2005-03-31 2010-11-27 Астеллас Фарма Инк. Производное соединение пропан-1,3-диона или его соль
RU2418803C2 (ru) * 2005-10-19 2011-05-20 Киссеи Фармасьютикал Ко., Лтд. Конденсированное гетероциклическое производное, содержащая его лечебная композиция и ее применение в медицине
US8765948B2 (en) 2007-11-07 2014-07-01 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
CA2788533C (en) 2010-02-10 2018-03-06 Kissei Pharmaceutical Co., Ltd. Choline salt of fused heterocyclic derivative and pharmaceutical composition containing the same
PE20141699A1 (es) 2012-01-16 2014-11-29 Bayer Ip Gmbh Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina
US20130224771A1 (en) 2012-02-21 2013-08-29 Northwestern University Anti-mullerian hormone detection in whole blood
JP6222094B2 (ja) 2012-09-07 2017-11-01 アステラス製薬株式会社 スルホニルアミジン化合物の製造法
WO2014042176A1 (ja) 2012-09-14 2014-03-20 キッセイ薬品工業株式会社 縮合複素環誘導体の製造方法およびその製造中間体
PT3415517T (pt) 2012-09-28 2022-05-13 Takeda Pharmaceuticals Co Forma cristalina de 1-(4-1-(2,6-difluorobenzil)-5- dimetilaminometil-3-(6-metoxipiridazin-3-il)-2,4-dioxo- 1,2,3,4-tetrahidrotieno(2,3-d)-pirimidin-6-il)fenil)-3- metoxiureia
WO2014143669A1 (en) 2013-03-15 2014-09-18 AbbVie Inc . Compositions for use in treating heavy menstrual bleeding and uterine fibroids
AR095785A1 (es) 2013-04-09 2015-11-11 Bayer Pharma AG Derivados de espiroindolina y composiciones farmacéutica de los mismos
US9949974B2 (en) 2015-09-01 2018-04-24 Abbvie Inc. Methods of adminstering elagolix
BR112019002513A2 (pt) 2016-08-08 2019-05-14 Kissei Pharmaceutical Co., Ltd. uso e dosagem de agentes terapêuticos para endometriose
ES2912929T5 (en) 2016-09-30 2025-05-09 Sumitomo Pharma Switzerland Gmbh Methods of treating uterine fibroids and endometriosis
US11980621B2 (en) 2017-06-05 2024-05-14 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
EP4509173A3 (en) 2017-06-05 2025-06-04 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
US20230067378A1 (en) 2018-11-07 2023-03-02 ObsEva S.A. Compositions and methods for the treatment of estrogen-dependent disorders

Also Published As

Publication number Publication date
JP7348171B2 (ja) 2023-09-20
JP2020522571A (ja) 2020-07-30
CA3066190A1 (en) 2018-12-13
WO2018224498A1 (en) 2018-12-13
US11980621B2 (en) 2024-05-14
JP2023113715A (ja) 2023-08-16
AU2018280742B2 (en) 2023-12-21
CN110996956A (zh) 2020-04-10
KR20200027481A (ko) 2020-03-12
US20200138819A1 (en) 2020-05-07
MX2019014483A (es) 2020-08-17
SG11201911598WA (en) 2020-01-30
US20240293414A1 (en) 2024-09-05
EA201992612A1 (ru) 2020-05-20
JP7657855B2 (ja) 2025-04-07
KR102839190B1 (ko) 2025-07-28
AU2018280742A1 (en) 2020-01-30
MA49256A (fr) 2021-05-26
AU2024201701B2 (en) 2025-04-10
EP3634418A1 (en) 2020-04-15
AU2024201701A1 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
JP7657855B2 (ja) 子宮内膜症の治療のためのゴナドトロピン放出ホルモンアンタゴニスト投与計画
JP7485815B2 (ja) 子宮筋腫を治療し、月経失血を低下させるゴナドトロピン放出ホルモンアンタゴニスト投与計画
US20230067378A1 (en) Compositions and methods for the treatment of estrogen-dependent disorders
US20220288154A1 (en) Gnrh antagonists for the treatment of estrogen-dependent disorders
US20220305017A1 (en) Compositions and methods for the treatment of estrogen-dependent disorders
US12280052B2 (en) Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
EA044130B1 (ru) Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза
EA049129B1 (ru) Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения миомы матки и уменьшения менструальной кровопотери
HK40027583A (en) Dosing regimen comprising a gonadotropin-releasing hormone antagonist for treating uterine fibroids and reducing menstrual blood loss

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)